HomeIONS • NASDAQ
Ionis Pharmaceuticals Inc
$43.65
Mar 28, 12:32:07 PM GMT-4 · USD · NASDAQ · Disclaimer
Top loserStockUS listed securityUS headquartered
Previous close
$44.66
Day range
$43.65 - $44.95
Year range
$34.32 - $54.44
Market cap
6.36B USD
Avg Volume
1.26M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
324.50M113.65%
Operating expense
51.01M6.38%
Net income
-9.26M82.33%
Net profit margin
-2.8591.74%
Earnings per share
0.12109.98%
EBITDA
18.74M109.26%
Effective tax rate
-234.77%—
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
2.34B17.03%
Total assets
2.99B18.00%
Total liabilities
2.60B32.76%
Total equity
386.69M—
Shares outstanding
145.75M—
Price to book
16.66—
Return on assets
1.31%—
Return on capital
2.15%—
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-9.26M82.33%
Cash from operations
32.86M116.42%
Cash from investing
-26.71M-112.59%
Cash from financing
40.72M179.82%
Net change in cash
47.21M222.55%
Free cash flow
58.22M149.63%
About
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis. The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Founded
1989
Employees
927
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu